Buscar
Capricor Therapeutics Inc
CAPRAñadir a la lista de seguimiento
3.850USD
-0.340-8.11%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
222.96MCap. mercado
PérdidaP/E TTM
Más Datos de Capricor Therapeutics Inc Compañía
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. It leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.
Información de Capricor Therapeutics Inc
Símbolo de cotizaciónCAPR
Nombre de la empresaCapricor Therapeutics Inc
Fecha de salida a bolsaJun 04, 2002
Director ejecutivoMarban (Linda)
Número de empleados160
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 04
Dirección10865 Road to the Cure
CiudadSAN DIEGO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal92121
Teléfono13103583200
Sitio Webhttps://capricor.com/
Símbolo de cotizaciónCAPR
Fecha de salida a bolsaJun 04, 2002
Director ejecutivoMarban (Linda)
Ejecutivos de Capricor Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Linda Marban, Ph.D.
Dr. Linda Marban, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
212.02K
--
Mr. David B. Musket
Mr. David B. Musket
Independent Director
Independent Director
88.79K
--
Mr. Anthony Bergmann
Mr. Anthony Bergmann
Chief Financial Officer
Chief Financial Officer
11.22K
--
Dr. Frank I. Litvack, M.D.
Dr. Frank I. Litvack, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Ms. Karen G. Krasney, J.D.
Ms. Karen G. Krasney, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
--
--
Mr. George W. Dunbar, Jr.
Mr. George W. Dunbar, Jr.
Independent Director
Independent Director
--
--
Ms. Karimah Es Sabar
Ms. Karimah Es Sabar
Independent Director
Independent Director
--
--
Dr. Paul Auwaerter, M.D.
Dr. Paul Auwaerter, M.D.
Independent Director
Independent Director
--
--
Dr. Philip J. (Phil) Gotwals, Ph.D.
Dr. Philip J. (Phil) Gotwals, Ph.D.
Independent Director
Independent Director
--
--
Mr. Michael Kelliher
Mr. Michael Kelliher
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Linda Marban, Ph.D.
Dr. Linda Marban, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
212.02K
--
Mr. David B. Musket
Mr. David B. Musket
Independent Director
Independent Director
88.79K
--
Mr. Anthony Bergmann
Mr. Anthony Bergmann
Chief Financial Officer
Chief Financial Officer
11.22K
--
Dr. Frank I. Litvack, M.D.
Dr. Frank I. Litvack, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Ms. Karen G. Krasney, J.D.
Ms. Karen G. Krasney, J.D.
Executive Vice President, General Counsel
Executive Vice President, General Counsel
--
--
Mr. George W. Dunbar, Jr.
Mr. George W. Dunbar, Jr.
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Capricor Therapeutics Inc?
Los cinco principales accionistas de Capricor Therapeutics Inc son: Dr. Linda Marban, Ph.D.
¿Cuántas instituciones poseen acciones de Capricor Therapeutics Inc (CAPR)?
A fecha de 2026Q1, 325 instituciones poseen acciones de Capricor Therapeutics Inc, con un valor de mercado combinado de aproximadamente 31.81M, lo que representa el 54.99% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 10164129.00.